Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer

Xiaolin Yu, Sharad A Ghamande, Haitao Liu, Lu Xue, Shuhua Zhao, Wenxi Tan, Lijing Zhao, Shou-Ching Tang, Daqing Wu, Hasan Korkaya, Nita Jane Maihle, HongYan Liu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

HER family members are interdependent and functionally compensatory. Simultaneously targeting EGFR/HER2/HER3 by antibody combinations has demonstrated superior treatment efficacy over targeting one HER receptor. However, antibody combinations have their limitations, with high immunogenicity and high cost. In this study, we have developed a three-in-one nucleic acid aptamer-small interfering RNA (siRNA) chimera, which targets EGFR/HER2/HER3 in one molecule. This inhibitory molecule was constructed such that a single EGFR siRNA is positioned between the HER2 and HER3 aptamers to create a HER2 aptamer-EGFR siRNA-HER3 aptamer chimera (H2EH3). EGFR siRNA was delivered into HER2-expressing cells by HER2/HER3 aptamer-induced internalization. HER2/HER3 aptamers act as antagonist molecules for blocking HER2 and HER3 signaling pathways and also as tumor-targeting agents for siRNA delivery. H2EH3 enables down-modulation of the expression of all three receptors, thereby triggering cell apoptosis. In breast cancer xenograft models, H2EH3 is able to bind to breast tumors with high specificity and significantly inhibits tumor growth via either systemic or intratumoral administration. Owing to low immunogenicity, ease of production, and high thermostability, H2EH3 is a promising therapeutic to supplement current single HER inhibitors and may act as a treatment for HER2+ breast cancer with intrinsic or acquired resistance to current drugs.

Original languageEnglish (US)
Pages (from-to)317-330
Number of pages14
JournalMolecular Therapy - Nucleic Acids
Volume10
DOIs
StatePublished - Mar 2 2018

Fingerprint

Small Interfering RNA
Breast Neoplasms
Nucleotide Aptamers
Antibodies
Heterografts
Nucleic Acids
Neoplasms
Apoptosis
Costs and Cost Analysis
Growth
Pharmaceutical Preparations
Therapeutics

Keywords

  • EGFR
  • HER family
  • HER2
  • HER3
  • aptamer
  • breast cancer
  • non-immunogenicity
  • nontoxic
  • siRNA
  • trastuzumab resistance

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer. / Yu, Xiaolin; Ghamande, Sharad A; Liu, Haitao; Xue, Lu; Zhao, Shuhua; Tan, Wenxi; Zhao, Lijing; Tang, Shou-Ching; Wu, Daqing; Korkaya, Hasan; Maihle, Nita Jane; Liu, HongYan.

In: Molecular Therapy - Nucleic Acids, Vol. 10, 02.03.2018, p. 317-330.

Research output: Contribution to journalArticle

Yu, Xiaolin ; Ghamande, Sharad A ; Liu, Haitao ; Xue, Lu ; Zhao, Shuhua ; Tan, Wenxi ; Zhao, Lijing ; Tang, Shou-Ching ; Wu, Daqing ; Korkaya, Hasan ; Maihle, Nita Jane ; Liu, HongYan. / Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer. In: Molecular Therapy - Nucleic Acids. 2018 ; Vol. 10. pp. 317-330.
@article{29c4cc8a06404f868c16ff84c9fa655f,
title = "Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer",
abstract = "HER family members are interdependent and functionally compensatory. Simultaneously targeting EGFR/HER2/HER3 by antibody combinations has demonstrated superior treatment efficacy over targeting one HER receptor. However, antibody combinations have their limitations, with high immunogenicity and high cost. In this study, we have developed a three-in-one nucleic acid aptamer-small interfering RNA (siRNA) chimera, which targets EGFR/HER2/HER3 in one molecule. This inhibitory molecule was constructed such that a single EGFR siRNA is positioned between the HER2 and HER3 aptamers to create a HER2 aptamer-EGFR siRNA-HER3 aptamer chimera (H2EH3). EGFR siRNA was delivered into HER2-expressing cells by HER2/HER3 aptamer-induced internalization. HER2/HER3 aptamers act as antagonist molecules for blocking HER2 and HER3 signaling pathways and also as tumor-targeting agents for siRNA delivery. H2EH3 enables down-modulation of the expression of all three receptors, thereby triggering cell apoptosis. In breast cancer xenograft models, H2EH3 is able to bind to breast tumors with high specificity and significantly inhibits tumor growth via either systemic or intratumoral administration. Owing to low immunogenicity, ease of production, and high thermostability, H2EH3 is a promising therapeutic to supplement current single HER inhibitors and may act as a treatment for HER2+ breast cancer with intrinsic or acquired resistance to current drugs.",
keywords = "EGFR, HER family, HER2, HER3, aptamer, breast cancer, non-immunogenicity, nontoxic, siRNA, trastuzumab resistance",
author = "Xiaolin Yu and Ghamande, {Sharad A} and Haitao Liu and Lu Xue and Shuhua Zhao and Wenxi Tan and Lijing Zhao and Shou-Ching Tang and Daqing Wu and Hasan Korkaya and Maihle, {Nita Jane} and HongYan Liu",
year = "2018",
month = "3",
day = "2",
doi = "10.1016/j.omtn.2017.12.015",
language = "English (US)",
volume = "10",
pages = "317--330",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer

AU - Yu, Xiaolin

AU - Ghamande, Sharad A

AU - Liu, Haitao

AU - Xue, Lu

AU - Zhao, Shuhua

AU - Tan, Wenxi

AU - Zhao, Lijing

AU - Tang, Shou-Ching

AU - Wu, Daqing

AU - Korkaya, Hasan

AU - Maihle, Nita Jane

AU - Liu, HongYan

PY - 2018/3/2

Y1 - 2018/3/2

N2 - HER family members are interdependent and functionally compensatory. Simultaneously targeting EGFR/HER2/HER3 by antibody combinations has demonstrated superior treatment efficacy over targeting one HER receptor. However, antibody combinations have their limitations, with high immunogenicity and high cost. In this study, we have developed a three-in-one nucleic acid aptamer-small interfering RNA (siRNA) chimera, which targets EGFR/HER2/HER3 in one molecule. This inhibitory molecule was constructed such that a single EGFR siRNA is positioned between the HER2 and HER3 aptamers to create a HER2 aptamer-EGFR siRNA-HER3 aptamer chimera (H2EH3). EGFR siRNA was delivered into HER2-expressing cells by HER2/HER3 aptamer-induced internalization. HER2/HER3 aptamers act as antagonist molecules for blocking HER2 and HER3 signaling pathways and also as tumor-targeting agents for siRNA delivery. H2EH3 enables down-modulation of the expression of all three receptors, thereby triggering cell apoptosis. In breast cancer xenograft models, H2EH3 is able to bind to breast tumors with high specificity and significantly inhibits tumor growth via either systemic or intratumoral administration. Owing to low immunogenicity, ease of production, and high thermostability, H2EH3 is a promising therapeutic to supplement current single HER inhibitors and may act as a treatment for HER2+ breast cancer with intrinsic or acquired resistance to current drugs.

AB - HER family members are interdependent and functionally compensatory. Simultaneously targeting EGFR/HER2/HER3 by antibody combinations has demonstrated superior treatment efficacy over targeting one HER receptor. However, antibody combinations have their limitations, with high immunogenicity and high cost. In this study, we have developed a three-in-one nucleic acid aptamer-small interfering RNA (siRNA) chimera, which targets EGFR/HER2/HER3 in one molecule. This inhibitory molecule was constructed such that a single EGFR siRNA is positioned between the HER2 and HER3 aptamers to create a HER2 aptamer-EGFR siRNA-HER3 aptamer chimera (H2EH3). EGFR siRNA was delivered into HER2-expressing cells by HER2/HER3 aptamer-induced internalization. HER2/HER3 aptamers act as antagonist molecules for blocking HER2 and HER3 signaling pathways and also as tumor-targeting agents for siRNA delivery. H2EH3 enables down-modulation of the expression of all three receptors, thereby triggering cell apoptosis. In breast cancer xenograft models, H2EH3 is able to bind to breast tumors with high specificity and significantly inhibits tumor growth via either systemic or intratumoral administration. Owing to low immunogenicity, ease of production, and high thermostability, H2EH3 is a promising therapeutic to supplement current single HER inhibitors and may act as a treatment for HER2+ breast cancer with intrinsic or acquired resistance to current drugs.

KW - EGFR

KW - HER family

KW - HER2

KW - HER3

KW - aptamer

KW - breast cancer

KW - non-immunogenicity

KW - nontoxic

KW - siRNA

KW - trastuzumab resistance

UR - http://www.scopus.com/inward/record.url?scp=85042632892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042632892&partnerID=8YFLogxK

U2 - 10.1016/j.omtn.2017.12.015

DO - 10.1016/j.omtn.2017.12.015

M3 - Article

AN - SCOPUS:85042632892

VL - 10

SP - 317

EP - 330

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

ER -